CHE
Health check
See the tests
- ✓Positive net income
- ✓Positive operating cash flow
- ✗Return on assets improved
- ✓Cash flow above net income
- ✗Long-term debt / assets fell
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by Coteau from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Live chart
What they do
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration.
For information only · Important disclosures
Grades vs sector
Momentum50th percentile in sectorC+
Percentile within its GICS sector across the S&P 1500.
Growth52nd percentile in sectorC+
Percentile within its GICS sector across the S&P 1500.
Value45th percentile in sectorC
Percentile within its GICS sector across the S&P 1500.
Profitability72nd percentile in sectorB+
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.51 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
cheaper
pricier
pricier
cheaper
pricier
cheaper
Forward EPS $27.52 vs trailing $19.88 (+38% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score 10.4 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $2.5B | $265.2M | $325.5M |
| 2024 | $2.4B | $302.0M | $368.0M |
| 2023 | $2.3B | $272.5M | $273.4M |
| 2022 | $2.1B | $249.6M | $252.6M |
| 2021 | $2.1B | $268.6M | $249.9M |
| 2020 | $2.1B | $319.5M | $430.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +5.8%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | 5.60 | 6.06 | +8.2% |
| 2026-04-23 | 5.30 | 5.65 | +6.6% |
| 2026-02-25 | 7.03 | 6.42 | -8.7% |
| 2025-10-28 | 5.37 | 5.27 | -1.8% |
| 2025-07-29 | 4.98 | 4.27 | -14.3% |
| 2025-04-23 | 5.55 | 5.63 | +1.5% |
| 2025-02-26 | 6.78 | 6.83 | +0.7% |
| 2024-10-29 | 5.76 | 5.64 | -2.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-03-31 | $657.5M | +1.6% |
| 2025-12-31 | $639.3M | – |
| 2025-09-30 | $624.9M | – |
| 2025-06-30 | $618.8M | – |
| 2025-03-31 | $646.9M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Recent dividends
Insider trades
$1.0M
$1.0M
$1.1M
$541.0K
$1.1M
$101.1K
–
–
–
–
–
–
Stats refreshed 2026-10-21 18:23:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026